1 – 9 of 9
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.
(
- Contribution to journal › Article
- 2014
-
Mark
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
(
- Contribution to journal › Article
-
Mark
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
2014) In Diabetes therapy : research, treatment and education of diabetes and related disorders(
- Contribution to journal › Article
- 2012
-
Mark
Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes.
(
- Contribution to journal › Article
- 2009
-
Mark
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes.
(
- Contribution to journal › Article
-
Mark
Characterization of the Influence of Vildagliptin on Model-Assessed {beta}-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia.
(
- Contribution to journal › Article
- 2005
-
Mark
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
(
- Contribution to journal › Article
- 2004
-
Mark
Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes.
(
- Contribution to journal › Article
-
Mark
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
(
- Contribution to journal › Article